OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

Sotagliflozin (Sota) inhibits sodium glucose cotransporter 2 (SGLT2; IC(50)=1.8 nM) and SGLT1 (IC(50)=36 nM). In humans, Sota improves glycemic control in part by increasing urinary glucose excretion via renal SGLT2 inhibition. Sota also lowers postprandial glucose (PPG), likely by inhibiting intest...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Powell, David, Zambrowicz, Brian, Morrow, Linda, Beysen, Carine, Hompesch, Marcus, Turner, Scott, Hellerstein, Marc, Banks, Phillip, Strumph, Paul, Lapuerta, Pablo
Médium: Artigo
Jazyk:Inglês
Vydáno: Endocrine Society 2019
Témata:
Diabetes Mellitus and Glucose Metabolism
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555054/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR22-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky